To estimate the increase in prostate cancer mortality (PCM) and the reduction in overtreatment resulting from different active surveillance (AS) protocols, compared with treating men immediately.
Introduction
In a time of widespread debate about PSA screening for prostate cancer, active surveillance (AS) has emerged as a way to prevent the unnecessary treatment of some patients with prostate cancer, or at least to delay the treatment of the disease [1] . The benefit of not treating a patient immediately is the avoidance of the side effects of radical treatment.
Management by AS consists of the careful monitoring of men diagnosed with prostate cancer, but not yet treated, with PSA tests or repeat biopsies. What still needs to be determined is whether the benefits of avoiding side effects outweigh the risk that a patient misses his cure window by not being treated immediately.
There are currently a number of cohort studies designed to answer this question, including the Prostate Cancer Research International Active Surveillance (PRIAS) study [2] and the University of California at San Francisco (UCSF) [3] , the Johns Hopkins (JH) [4] and the Toronto cohort [5] studies among others [6, 7] ; however, with the exception of the Toronto cohort, their median follow-up times were <5 years. In the latest publications of these studies, very few deaths from prostate cancer were reported [2] [3] [4] [5] 7] .
Most AS cohorts contain only one AS protocol, usually selecting low-risk patients, with stage <T2a and Gleason score ≤6 disease [6, 7] . While in some cohorts follow-up biopsies occur yearly (e.g. the JH cohort [4] ), in others, biopsy occurs up to every 3 years after the first year (e.g. the PRIAS cohort [2] ).
It is not yet clear whether AS is safe for men with intermediate-risk prostate cancer. Although the UCSF cohort study [3] found that the 4-year treatment-free survival (TFS) rate did not significantly differ between men in the low-and men in the intermediate-risk groups, the intermediate-risk group had significantly worse outcomes in the Toronto cohort [5] .
Given the multitude of possible avenues for selecting and following men during AS, and the limited follow-up data, the use of modelling to evaluate the outcomes of AS protocols is necessary. Xia et al. [9] compared immediate radical prostatectomy (RP) and AS for low-risk patients in a simulation study and found that AS had a modest effect on prostate cancer mortality (PCM).
In the present study, we used a well-validated simulation model of the natural history of prostate cancer, MISCAN, which uses AS data from the JH cohort to predict TFS, Gleason score and volume progression. We projected the lifetime risk of PCM and overtreatment in the situation where AS is used to manage men with newly screen-detected low-and intermediate-risk prostate cancer, with different follow-up biopsy intervals, and we compared these strategies with that of treating all men immediately.
Methods

Simulation Model
MISCAN is a microsimulation model, which simulates individual life histories. A detailed description is available at http://cisnet.cancer.gov/prostate/profiles.html and in previously published studies [10] [11] [12] [13] . The model contains 18 health states, before detection of prostate cancer or death, corresponding to the combination of three stages (T1, T2 and T3), thee grades (Gleason score < 7, 7 and > 7) and whether or not cancer is metastasized. Additionally, men with T2 stage Gleason score 6 cancer are classified as T2a or T2bc and men with Gleason score 7 are classified as 3+4 or 4+3, depending on their remaining lead-time and age group, with their respective proportions based on European Randomized Study of Screening for Prostate Cancer (ERSPC) data. Some natural history variables were calibrated to ERSPC data (durations, transition probabilities, among others), while PSA growth variables were calibrated jointly to Surveillance, Epidemiology and End Results (SEER) incidence and ERSPC PSA distribution [13] .
In case the patient has prostate cancer detected outside of screening ('clinically detected') we assume that he is immediately treated. If his prostate cancer is screen-detected he can either be immediately treated or be assigned to AS.
If immediately treated, we assumed an equal chance of being referred to RP or radiation therapy (RT). Prostate cancer survival without treatment was estimated based on SEER data from the pre-PSA era (1983) (1984) (1985) (1986) ); this was assigned at clinical detection and depended on stage and grade. To correct for improvements on the survival not directly associated with screening or primary treatment, we added a hazard ratio for prostate cancer survival of 0.82, which was calibrated to the observed PCM in the ERSPC control (no screening) group (Table S1 ).
The hazard ratios for prostate cancer survival after radical treatment were 0.56 for RP based on Bill-Axelson et al. [14] and 0.63 for RT (maintaining the same ratio of benefit between RP and RT as in Etzioni et al. [15] ). The effect of early detection was applied through an additional probability of cure which decreased exponentially with lead-time for non-metastatic cases, Cure probability = 1 À exp(cure parameter * lead-time).
The cure parameter was calibrated to the observed PCM reduction in the ERSPC trial after 11 years of follow-up and was equal to À0.22. (Tables S1 and S2; Figure S1 ).
Modelling Referral to Treatment in AS
A patient on AS may be referred to treatment for four reasons: volume progression; Gleason score upgrade; clinical detection; and absence of evidence of biopsy progression. If any of these events occurred then we assumed in all cases that men were treated (Table 1) .
Because the benefit of screening is dependent on lead-time, men who are referred to AS will experience a smaller benefit of screening, depending on how much time they are on AS. For instance, a patient with a lead-time of 10 years at screen detection, referred to immediate treatment, will have a probability of cure as follows: 1À exp(À0.22 * 10) = 0.89. That is, there is an 89% probability that he will be cured, and an 11% probability that he will die from prostate cancer. If the patient were to choose AS and be referred to treatment 6 years later, his corresponding cure would become, 1À exp (À0.22 * 4) = 0.59.
We defined TFS as time from screen detection to radical treatment. We validated TFS projected by the model, together with the number of men who experienced volume or Gleason score upgrade, with data from the JH study on AS (Table 2 ). We simulated the study 100 times, by selecting men to undergo AS, with approximately the same age distribution and entrance criteria as those in the JH cohort (maximum disease state: T1 stage, Gleason score 6 and PSA level ≤ 10 ng/mL; Table 2 ).
Screening and Active Surveillance Policies
We sampled 10 million men representative of the age distribution in the USA, based on US life tables. In the base case, we screened men yearly between 55 and 69 years, with a PSA threshold for biopsy referral (PSAt) of 4 ng/mL, with biopsy compliance based on the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), and with every man with screen-detected prostate cancer immediately treated.
We compared the outcomes of treating every man immediately, with admitting men with low-risk prostate cancer (≤ T2a, Gleason score 6, PSA <10 ng/mL) into an AS programme. We ran a set of AS protocols where, after the first year, biopsy frequency was reduced to every 2, 3 or 5 years. We also projected the effects of AS, with a reduced (biannual) and increased (annual, up to age 74 years) screening schedule. Assuming that the referral rates from AS to radical treatment for men with intermediate-risk cancer (≤ T2 stage and 3+4 Gleason) were similar to those for men with low-risk cancer [7] , we also projected the effects of admitting men at low and intermediate risk (≤ T2 stage, 3+4 Gleason) into an AS programme (Table 3) .
Outcomes
The main outcome measures were the lifetime risk of PCM, treatment-free life years (TFLY), defined as the duration from onset of the disease until treatment, and the probability of overtreatment (defined as the risk that a man would be referred to radical treatment, and would not be clinically detected in absence of screening, or in other words, an overdiagnosed man who receives radical treatment). Additionally, we reported the average number of years spent on AS, the probability of PCM as a result of entering AS and the proportion of men in AS left untreated.
Sensitivity Analyses
We ran the non-AS, yearly and every 3-year biopsy protocols, in combination with differential screening intensities and referral rates to treatment while on AS. We also examined the effect of no efficacy of treatment, and referring men only to either RP or RT ( Table 2 ). As the model variables were subject to uncertainty, we ran a multivariate probabilistic sensitivity analysis including, the cure parameter, hazard ratios for treatment and the probabilities of detection while on AS (Table 4) . We also examined the assumption of an exponentially decreasing cure benefit, by comparing the best fit, with the fit of a linearly decreasing cure benefit (Table S2) . AS, active surveillance; TFS, treatment-free survival. *2011 follow-up report of the Johns Hopkins cohort [3] showed there were no prostate cancer deaths in the AS cohort. The latest update [16] showed a prostate cancer survival rate of 99.9% at 10 years. MISCAN predicted two prostate cancer deaths vs the zero number of deaths observed in Tosoian et al. [3] .
(a) As in Tosoian et al. [3] . This was updated in [16] , where the TFS at 5 years was 61%. 
Results
Active Surveillance with Different Entrance Criteria and Follow-Up Protocols
Screening yearly between ages 55 and 69 years, with a PSAt of 4 ng/mL (base case), and treating every man immediately was found to result in a lifetime risk of PCM of 2.6%. This strategy amounted to 7.4 TFLY per person, which contrasted with 8.7 TFLY per person (17.3% increase) if no PSA-based screening was performed and every man was treated immediately. No screening was found to result in a lifetime risk of PCM of 3.3% (Table 5) .
On average, patients who entered AS remained untreated between 5.8 and 9.0 years depending on the screening and AS policy. If men with T2a Gleason score 6 disease were referred to AS then PCM would increase to 2.6% (1.0% increase), TFLY per person would increase from 7.4 to 7.7 and overtreatment would be reduced from 2.5 to 2.1% (18% reduction). About 27% of all men referred to AS remained untreated and the probability of dying as a result of undergoing AS was 1.8%.
Increasing the biopsy interval after the first year of follow-up from yearly, to 2, 3 or 5 years would increase PCM to~2.6% (from 1.0% to 1.7, 2.3 and 3.2%, respectively), and the proportion of men who would die from prostate cancer as a result of undergoing AS rises from 1.8% to 3.0, 4.1 and 5.9%, respectively. Conversely, the probability of overtreatment is reduced from 2.1 to 2.0% (25% reduction), 1.9% (30% reduction) and 1.8% (36% reduction), respectively. The average time spent on AS increases from 5.9 to 9.0 years.
Referring men with intermediate-risk disease to AS increases PCM to~2.6% (2.7% increase), while overtreatment decreases from 2.5 to 2.0% (23.1% decrease). The risk of PCM as a result of undergoing AS was 3.6%. By contrast, if we only admit low-risk men and with biennial biopsies after the first year, the risk of PCM resulting from AS is only 3.0%, but there would be a higher reduction in overdiagnosis (25.4% decrease). For univariate and multivariate sensitivity analyses see Tables S2-S5 and Fig. S2 .
Active Surveillance with Different Screening Intensities
In the situation where every man is immediately treated, increasing the stopping age to 74 years or increasing biopsy compliance lowers the PCM from 2.6 to 2.4% (7.4 and 6.1% Table 3 Active surveillance protocols and screening policies considered. Probability of volume progression T2a 0.1 Uniform, Min = 20%, Max = +20% Probability of volume progression >T2a 0.4 Uniform, Min = À20%, Max = +20% Sensitivity for Gleason progression 0.5 Uniform, Min = À20%, Max = +20% Probability of leaving AS without progression 0.04 Uniform, Min = À20%, Max = +20%
AS, active surveillance; RP, radical prostatectomy; RT, radiation therapy. *Hazard ratio is relative to the survival without treatment and is based on Bill-Axelson et al. [14] . For hazard ratio of RT, we extrapolated based on the same ratio from Etzioni et al. [15] . †
The standard deviation was calculated such that the CI in [14] would include~95% of random draws. ‡ We first calculated how much would we need to vary the parameter until the model fit would become significantly worse, using 5% as a threshold for an increase or decrease in prostate cancer deaths (Table S2) . Using this as a CI for the parameter, we calculated a standard deviation such that 95% of the random draws would fall inside this CI. See also decrease, respectively). Conversely, the probability of overtreatment increases from 2.5 to 3.9% (35.3% increase) or 3.1% (18.5% increase). Introducing AS with a more intensive screening schedule seems to result in a larger effect, both on overtreatment reduction and PCM increase (Table 5) .
Discussion
In the present study we used a novel approach to modelling AS, by modelling rates of volume and Gleason score progression, instead of modelling durations [9] or by using a simplistic assumption of reduced treatment benefit for men on AS [17] .
Introducing AS for men with screen-detected disease results, on average, in an interval of between 5.8 and 9.0 TFLY, depending on the AS protocol. If we accept men with T2a Gleason score 6 prostate cancer into AS protocols, with yearly biopsies or a biopsy every 3 years after the first year, overtreatment reduces from 2.5 to 2.1% (18.4% reduction) or 1.9% (30.3% reduction), PCM remains~2.6% (1.0 or 2.3% increase), with a probability of dying from prostate cancer as a result of undergoing AS of 1.8 or 4.1%, respectively.
To put these numbers into perspective, in 2014,~233 000 men were expected to be diagnosed with prostate cancer in the USA [18] . Assuming half of them had their prostate cancer screen-detected between ages 55 and 69 years (116 500) and that 30% of these men had low-risk disease and were referred to AS (34 950), our model predicts that for men with yearly biopsies or a biopsy every 3 years after the first year, either~9250 or 14 250 men would not be overtreated and an extra 625 or 1450 men would die from prostate cancer as a result of entering AS, respectively.
Our sensitivity analyses showed that these effects will become larger if the intensity of screening increases (increased stopping age or higher biopsy compliance), as more screendetected prostate cancers are classified as low-risk and have a longer lead-time. Admitting men with intermediate-risk disease in AS seems not to be as efficient as increasing the biopsy interval in AS protocols for men at low risk.
Our modelling of AS used a previously validated model of the natural history of prostate cancer [10] [11] [12] [13] [14] , which is mostly based on ERSPC data [19] , with incidence in the USA validated to SEER data [13, 14] . By calibrating the sensitivity to Gleason progression and the probability of detecting TFLY, treatment-free life years. *All men included in AS protocols, had a PSA level < 10 ng/mL at diagnosis and a biopsy after 1 year. For instance, in the T2 GS6, 3-year biopsy protocol, the biopsy occurs at the 1st, 4th and 7th year. † Risk of PCM attributable to AS, is the difference in PCM between the situation where every man is immediately treated and where some men are referred to AS, depending on the specific AS protocol, divided by the number of men who entered into AS.
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© 2016 The Authors BJU International © 2016 BJU International volume progression, given that there is an increase in stage, we were able to match the TFS rate and the number of men experiencing volume and Gleason progression during AS to observed data in the JH cohort on AS. This has some advantages relative to calibration based only on an AS cohort. First, durations and transitions between health states (which in large part determine time on AS) were based on a large randomized controlled trial. Second, the median follow-up of the ERSPC trial was much larger than most AS cohorts, which makes our PCM projections potentially more reliable.
Conversely, MISCAN simplifies some of the AS protocol compared with the current practice in most AS cohorts. The entrance criteria for AS used in the MISCAN model include T-stage, Gleason score and PSA level, but not the number of positive cores or PSA density. Additionally, there is some variability regarding TFS rates, and number of men experiencing volume and/or Gleason progression among AS cohorts [6, 7] .
The results of the present study may not apply to the African-American population [20] , as the benefit of screening is estimated based on a European cohort, and the probabilities of referral to treatment while on AS are estimated based on a cohort with very few African-American men [4] .
In contrast, in the study by Xia et al. [9] , where AS was modelled as duration from diagnosis to treatment, our approach for modelling AS allows the effects of multiple AS strategies to be projected without resorting to multiple AS cohort datasets. An additional advantage of this framework is that it allows us to jointly model screening and AS strategies. The main disadvantage of this approach is that given the difficulty of modelling volume progression directly, we need to make the assumption that volume progression can only occur if there is an increase in T-stage in the model. Our validation shows that MISCAN is slightly more pessimistic than the data reported in the JH cohort (two vs zero deaths from prostate cancer). Other cohorts showed no PCM at 5 years except for the study by Klotz et al. [21] in which one death from prostate cancer was reported at 3.7 years of follow-up. This is probably attributable to the selection of patients with very low risk in most AS cohorts, which contrasts with the ERSPC population used to inform natural history in MISCAN.
Importantly, we verified that a key statistic, probability of dying as a result of AS, which was found to be 1.8% in our model, is in line with previous studies where no benefit of early detection is assumed, and where AS was modelled as duration from diagnosis to treatment (Xia et al. [9] : 1.2%) or as an assumption about reduced benefit (Hayes et al. [17] : 2%). This rate was also similar to the observed PCM (1.5%) in the Toronto cohort after 10 years of follow-up [6] .
In the present study we did not model quality of life. Heijnsdijk et al. [22] found that introducing quality-adjusted life years (QALYs) reduces the screening benefit by 23%. Delaying treatment with AS is a way to mitigate this reduction, because of the avoidance of side effects. For instance, Hayes et al. [17] compared AS with several forms of radical treatment and found that AS gives the highest expected QALYs. Using QALYs will probably favour AS protocols that are less biopsy-intensive, given the increased risk of biopsy complications [23] [24] [25] .
As previously suggested [1] [2] [3] [4] [5] [6] [7] [8] [9] , our model predicted that AS for low-risk men was relatively safe. We projected the harms of benefits of several AS strategies and we found that if we increased the interval between biopsies after the first year to 3 years, which is close to the strategy used in the PRIAS cohort [2] , overtreatment may be reduced by up to 30%, although with a small increase in PCM. These results are most applicable to a US population of European ancestry.
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